P
Peter S. Nelson
Researcher at Fred Hutchinson Cancer Research Center
Publications - 497
Citations - 57568
Peter S. Nelson is an academic researcher from Fred Hutchinson Cancer Research Center. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 96, co-authored 425 publications receiving 47923 citations. Previous affiliations of Peter S. Nelson include University of Washington & National Institutes of Health.
Papers
More filters
Posted ContentDOI
Griffin: Framework for clinical cancer subtyping from nucleosome profiling of cell-free DNA
Anna-Lisa Doebley,Anna-Lisa Doebley,M. Ko,H. Liao,A. E. Cruikshank,C. Kikawa,K. Santos,Joseph B. Hiatt,R. D. Patton,N. De Sarkar,Anna C. H. Hoge,K. Chen,Zachary Weber,M. Adil,M. Adil,Jonathan Reichel,Paz Polak,Viktor A. Adalsteinsson,Peter S. Nelson,Heather A. Parsons,Daniel G. Stover,David MacPherson,David MacPherson,Gavin Ha,Gavin Ha +24 more
TL;DR: Griffin this paper employs a novel GC correction procedure tailored to variable cfDNA fragment sizes, which improves the prediction of chromatin accessibility and achieved excellent performance for detecting tumor cfDNA in early-stage cancer patients.
Journal ArticleDOI
Reformation of the chondroitin sulfate glycocalyx enables progression of AR-independent prostate cancer
Nader Al-Nakouzi,Chris K. Wang,Htoo Zarni Oo,Irina Nelepcu,Nada Lallous,Charlotte B Spliid,N. Khazamipour,Joey C. Y. Lo,Sarah Truong,Colin Collins,Desmond Hui,Shaghayegh Esfandnia,Hans Adomat,Thomas Mandel Clausen,Tobias Gustavsson,Swati Choudhary,Robert Dagil,Eva Corey,Yuzhuo Wang,Anne Chauchereau,Ladan Fazli,Jeffrey D. Esko,Ali Salanti,Peter S. Nelson,Martin E. Gleave,Mads Daugaard +25 more
TL;DR: In this article , the authors show that changes in chondroitin sulfate (CS), a major glycosaminoglycan component of the tumor cell glycocalyx and extracellular matrix, is AR-regulated and promotes the adaptive progression of castration-resistant prostate cancer (CRPC) after ARPI.
Journal ArticleDOI
Contribution of mouse adrenal glands to intratumor androgens and growth of castration-resistant prostate cancer xenografts.
Elahe A. Mostaghel,Heather E. Biehl,Susanna Hernandez,Ailin Zhang,Jon Bartlett,Eva Corey,Trevor M. Penning,Riikka Oksala,Lawrence D. True,Peter S. Nelson +9 more
TL;DR: The impact of adrenalectomy (ADX) on suppressing tumor androgens and growth in two patient derived xenografts (PDX) models of castration resistant prostate cancer (CRPC) is determined.
ReportDOI
The Prostate Expression Database (PEDB)
TL;DR: The PEDB was extended to include sequence analysis of the murine prostate and a corresponding database, mPEDB, was constructed to facilitate the dissemination of mouse prostate gene expression information and the results show that these approaches are complementary.
Journal ArticleDOI
Clinical impact of PSMA PET in patients with biochemically recurrent prostate cancer after locoregional definitive therapy.
Avanti Gulhane,Rafee Talukder,Atreya Dash,William J. Ellis,G. Schade,Jonathan M. Chen,Emily Weg,Heather H. Cheng,Petros Grivas,Jessica Hawley,John Lee,R. Bruce Montgomery,Peter S. Nelson,Michael T. Schweizer,Todd Yezefski,Evan Y. Yu,Daniel W. Lin,Delphine L. Chen +17 more
TL;DR: PSMA PET may impact decision making in patients with BCR after treatment of localized prostate cancer, particularly for those with equivocal findings on conventional imaging, regardless of clinical risk at diagnosis.